Veritas Genetics

LetsGetChecked Names Avni Santani, PhD, FACMG, Chief Genomics Officer Following Acquisition of Veritas Genetics

Retrieved on: 
Wednesday, June 21, 2023
General Health, Health, Health Technology, Telemedicine, Virtual Medicine, Health Insurance, Informatics, American Society for Clinical Laboratory Science, University, College, CHOP, Texas A&M University, College of American Pathologists, Multimedia, Associate, Public sector, Organization, American Board of Commissioners for Foreign Missions, Pathology, FACMG, AI, Association for Molecular Pathology v. Myriad Genetics, Inc., Veritas Genetics, Medical genetics, Antibiotics, Genomics, Doctor of Philosophy, Genetics

LetsGetChecked, a global healthcare solutions company, announced today the appointment of Avni Santani, PhD, FACMG, to Chief Genomics Officer.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today the appointment of Avni Santani, PhD, FACMG, to Chief Genomics Officer.
  • She joins the team from Veritas Genetics, a pioneering genomics company that was acquired by LetsGetChecked in 2022.
  • Dr. Santani holds a Ph.D. in Genetics from Texas A&M University and is board-certified in clinical laboratory genetics and genomics by the American Board of Medical Genetics and Genomics (ABMGG).
  • “I am delighted to be continuing my work in genetics with LetsGetChecked,” said Dr. Avni Santani, Chief Genomics Officer at LetsGetChecked.

LetsGetChecked Introduces myPGx, a Pharmacogenomics Solution that Leverages the Power of Precision Medicine to Improve Patient Health with More Tailored Treatment Plans

Retrieved on: 
Tuesday, September 27, 2022
Health, Telemedicine, Virtual Medicine, Genetics, General Health, Pharmaceutical, Biotechnology, Health, Laboratory, Risk, Veritas Genetics, Disulfiram-like drug, Founder CEO, Prescription, Public sector, Population, EU, Patient, Genetics, Veritas, CEO, United Kingdom, CAP, CLIA, Pain management, Whole genome sequencing, Pharmaceutical industry, Health insurance

LetsGetChecked, a leading healthcare solutions company, announced today the launch of its inaugural genetics offering, myPGx, a pharmacogenomics solution.

Key Points: 
  • LetsGetChecked, a leading healthcare solutions company, announced today the launch of its inaugural genetics offering, myPGx, a pharmacogenomics solution.
  • The launch of myPGx expands the companys vertically integrated and modular healthcare platform, strengthening its commitment to creating equitable and comprehensive care across the entire patient lifecycle.
  • LetsGetCheckeds myPGx offering is a robust testing panel that identifies potential drug-gene interactions for +100 drugs across major disease categories, including behavioral health, cardiovascular health, and pain management.
  • Precision medicine has enormous potential to improve patient outcomes, reduce costs, heighten the customer experience, and shape the future of healthcare, said Peter Foley, Founder & CEO of LetsGetChecked.

Morgan Health Announces New Investment in LetsGetChecked, Expanding Access to At-Home Health Care

Retrieved on: 
Thursday, September 8, 2022
Health Technology, Health Insurance, Health, Telemedicine, Virtual Medicine, Partnership, Patient, HIV disease progression rates, Veritas Genetics, CEO, EU, NYSE, Health minister, Pharmacogenomics, Research, LTP, Kaiser Permanente, Human resources, JPMorgan Chase, API, Emerge Commerce, Investment, Organization, Public sector, JPM, Whole genome sequencing, Prevalence, Diabetes, COVID-19, National Operating Committee on Standards for Athletic Equipment, Growth, Health, Healthcare, Pharmaceutical industry, Castlight Health

These new offerings allow LetsGetChecked to support the full lifecycle of care across womens health, mens health, sexual health as well as general health and wellness.

Key Points: 
  • These new offerings allow LetsGetChecked to support the full lifecycle of care across womens health, mens health, sexual health as well as general health and wellness.
  • Morgan Healths investment in LetsGetChecked follows its recent investments in Vera Whole Health , and subsequent investment in Castlight Health , Embold Health , Centivo and research collaboration with Kaiser Permanente .
  • Morgan Health is a JPMorgan Chase business unit focused on improving employer-sponsored health care.
  • Through its investments and the advancement of accountable care, Morgan Health is working to improve the quality, equity and affordability of employer-sponsored health care for JPMorgan Chase employees, their families and the U.S. health system.

LetsGetChecked Completes Acquisition of BioIQ

Retrieved on: 
Tuesday, May 3, 2022
Technology, Insurance, Professional Services, Software, Other Health, Internet, Managed Care, Health, General Health, EU, United Kingdom, Veritas Genetics, Credit Suisse, SVB Leerink, Cooley LLP, Industry, Genomics, Government, Health, LLP, Public health, CLIA, Population health, Solution, News, CEO, Acquisition, Health insurance

Today, LetsGetChecked, a leading global healthcare solutions company, announced it has finalized the acquisition of BioIQ, an analytics-driven population health and diagnostics company.

Key Points: 
  • Today, LetsGetChecked, a leading global healthcare solutions company, announced it has finalized the acquisition of BioIQ, an analytics-driven population health and diagnostics company.
  • With this acquisition, LetsGetChecked gains a trusted partner with an extensive knowledge base and a breadth of experience in serving health plans and employer markets to deliver healthcare solutions at scale.
  • As a result of this acquisition, BioIQs consumers, health plan, government, and employer customers will have access to an even wider-reaching, best-in-class virtual care experience.
  • As previously announced, BioIQ will operate as a wholly-owned subsidiary of LetsGetChecked.

LetsGetChecked to Acquire Veritas Genetics and Veritas Intercontinental to Unlock the Future of Personalized At-Home Healthcare

Retrieved on: 
Tuesday, March 29, 2022
General Health, Genetics, Health, Practice Management, Whole genome sequencing, Â, United Kingdom, Genetics, Genomics, Hospital, CEO, Health, George Church (geneticist), Entrepreneurship, EU, Genome, Industry, Genetic testing, Harvard Medical School, MIT Technology Review, Veritas Genetics, Technology, Acquisition, MIT, Antibiotics, Medical imaging, Telescope, Pharmaceutical industry, Veritas, LETSGETCHECKED, VERITAS GENETICS

Veritas Genetics was co-founded in 2014 by Dr. George Church, a renowned pioneer in genomics from Harvard Medical School and MIT.

Key Points: 
  • Veritas Genetics was co-founded in 2014 by Dr. George Church, a renowned pioneer in genomics from Harvard Medical School and MIT.
  • We are excited to be a part of LetsGetChecked, a leader in at-home and virtual care, said Mirza Cifric, CEO of Veritas Genetics.
  • I expect these acquisitions will change the future of personalized healthcare as we know it, said Dr. George Church, Co-Founder of Veritas Genetics.
  • LetsGetCheckeds acquisition of Veritas Genetics and Veritas Intercontinental operations is expected to close in the first fiscal quarter of this year.

Global Genomics Market Research Report 2021: Focus on Functional Genomics & Pathway Analysis - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 14, 2021
Health, Genetics, Degenerative disease, Technology, Diabetes, Product, Severe acute respiratory syndrome coronavirus 2, CGH, Genome, Solution, Awareness, Cepheid variable, Biomedical Research, Gene, Adoption, Lists of diseases, Cancer, Breast cancer, Cepheid (company), Veritas Genetics, Academic health science centre, Efficiency, Data management, DNA, Karyotype, Patient, PCR, 23andMe, Functional genomics, COG-UK, NGS, COVID-19 Genomics UK Consortium, Biotechnology, Pathway analysis, Prognosis, Quest Diagnostics, COVID-19, Application, Genomics, Asia-Pacific, Thermo Fisher Scientific, Catalog, Consortium, Antibiotics, Vaccine, Animal

The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has also led to an increase in the market competition, coupled with the development of breakthrough genomic technologies by Veritas Genetics, 23andMe, and other key players.
  • In August 2020, Ancestry launched a new next-generation sequencing-based tool to screen genes linked to blood disorders, colon cancer, heart diseases, and breast cancer.
  • This product, developed by Quest Diagnostics, has a better DNA analysis efficiency when compared to microarray-based testing.

Veritas Intercontinental completes its perinatal services offering with the launch of myPrenatalWES, an innovative prenatal diagnostic test

Retrieved on: 
Wednesday, September 29, 2021
CGH, Biotechnology, Down syndrome, Genetic counseling, Patau, Deletion, Diagnosis, Sex, CNV, Recurrence, Intercontinental, Veritas Genetics, Health, Fortis Healthcare, Pregnancy, MECP2 duplication syndrome, Gene, Genomics, Non-functional testing, Child, Trisomy, Leadership, Genetics, Risk, Technology, Prognosis, Chromosome, NIPT, Quality of life, Medical imaging, Birth control, Medical device

MADRID, Sept. 29, 2021 /PRNewswire/ -- Veritas Intercontinental launches myPrenatalWES, a differential prenatal diagnostic test developed for at-risk pregnancies that provides, with a single technique, an analysis of deletions and duplications (CNVs or Copy Number Variants) along with the molecular study of genes related to fetal findings.

Key Points: 
  • - Veritas Intercontinental expands its range of perinatal services with the launch of myPrenatalWES, an innovative prenatal diagnostic test indicated for pregnancies with risk of genetic alteration.
  • - myPrenatalWES technology is a breakthrough because it allows, with a single test, to replace the different techniques used in prenatal diagnosis, shortening the response time, and maximizing the diagnostic yield.
  • -Veritas opened its state-of-the-art genetics laboratory in 2020, offering perinatal services to its global partners.
  • In the absence of findings, a second technique of sequencing of specific genes related to the ultrasound findings is necessary.

Veritas Intercontinental completes its perinatal services offering with the launch of myPrenatalWES, an innovative prenatal diagnostic test

Retrieved on: 
Wednesday, September 29, 2021
CGH, Biotechnology, Down syndrome, Genetic counseling, Patau, Deletion, Diagnosis, Sex, CNV, Recurrence, Intercontinental, Veritas Genetics, Health, Fortis Healthcare, Pregnancy, MECP2 duplication syndrome, Gene, Genomics, Non-functional testing, Child, Trisomy, Leadership, Genetics, Risk, Technology, Prognosis, Chromosome, NIPT, Quality of life, Medical imaging, Birth control, Medical device

MADRID, Sept. 29, 2021 /PRNewswire/ -- Veritas Intercontinental launches myPrenatalWES, a differential prenatal diagnostic test developed for at-risk pregnancies that provides, with a single technique, an analysis of deletions and duplications (CNVs or Copy Number Variants) along with the molecular study of genes related to fetal findings.

Key Points: 
  • - Veritas Intercontinental expands its range of perinatal services with the launch of myPrenatalWES, an innovative prenatal diagnostic test indicated for pregnancies with risk of genetic alteration.
  • - myPrenatalWES technology is a breakthrough because it allows, with a single test, to replace the different techniques used in prenatal diagnosis, shortening the response time, and maximizing the diagnostic yield.
  • -Veritas opened its state-of-the-art genetics laboratory in 2020, offering perinatal services to its global partners.
  • In the absence of findings, a second technique of sequencing of specific genes related to the ultrasound findings is necessary.